Notably, decreased insulin receptor function increases synaptic sensitivity to the binding of and dysfunction caused by Aβ18, and insulin and insulin-sensitizing therapy has been shown to be effective for cognition in mouse models of AD as well as in patients with mild cognitive impairment (MCI) or early AD18–22. This evidence concerns the gene INS and Alzheimer disease.